MedTrace Logo

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

NCT02826603 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1114

Last updated 2019-07-09

Study results available
· View outcomes & findings →

Summary

Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

Secukinumab

300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48

DRUG

Ustekinumab

Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-22
Primary Completion
2018-07-09
Completion
2018-07-09
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Czechia
  • Guatemala
  • Hungary
  • Iceland
  • Malaysia
  • Poland
  • Slovakia
  • South Korea
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02826603 on ClinicalTrials.gov